Why Medical Device Design Changes Matter

The ISO 10993-1 standard outlines scenarios where a biocompatibility reassessment is necessary after a design change:

1. Material Changes: Switching materials or modifying formulations can affect how a device interacts with biological tissues.
2. Manufacturing Modifications: Changes in processes like sterilisation, packaging, or production methods can alter the device’s biological profile.
3. Storage or Transport Changes: Alterations to storage conditions, such as shelf life or temperature, could affect the device’s integrity.
4. Changes in Intended Use: Shifts in a device’s clinical application may require new testing to ensure it remains safe for its intended purpose.
5. Evidence of Adverse Effects: New data showing harmful biological effects necessitates an immediate re-assessment.

Impact of Medical Devices Material and Process Changes

Medical devices must adhere to rigorous safety standards, but even
minor design changes (whether to materials, functionality, or
manufacturing processes) can significantly affect biocompatibility.
Biocompatibility refers to how well a device interacts with biological
tissue during its intended use, without causing adverse effects. When a device’s design changes, it’s essential to re-evaluate its biocompatibility to ensure patient safety.

Medical Device Material Modifications

Changes in materials can significantly alter a device’s leachable profile – substances that may migrate from the device into the body. Even slight
alterations to material composition, like adjusting the concentration of additives, can introduce new chemicals that might provoke toxicity, sensitivity,
or inflammation. Materials initially chosen for biocompatibility may no longer be suitable if modified, requiring additional testing to assess potential biological impacts.

Medical Device Surface Treatments and Coatings

Coatings or alterations to surface treatments are common design changes. While coatings can enhance device performance (e.g., by reducing
friction or improving durability), they can also impact biocompatibility. New coatings may introduce harmful substances or change how the device interacts with tissues, potentially leading to irritation or inflammation. Additionally, changes in the device’s physical properties, such as texture or smoothness, can affect tissue responses.

Medical Device Geometric Changes

The shape, size, and structure of a device are crucial to how it interacts with the body. Increasing surface area or changing geometry may raise the likelihood of adverse tissue reactions. For example, complex geometries in an implantable device can result in higher wear rates, potentially releasing particles or causing
degradation that affects surrounding tissues. Evaluating these changes is particularly important for long-term implantable devices, where the risks may be magnified over time.

Medical Device Functional Modifications

Changes to a device’s intended use, such as extending its duration of use or altering the type of tissue it interacts with, can influence its biological impact. For example, a device that was originally designed for short-term use may
now be intended for long-term implantation. This shift may require a broader biocompatibility evaluation to assess new risks, including systemic effects and local tissue responses.

Changes to Packaging and Sterilisation Methods

Changes to packaging or sterilisation methods can also affect a device’s biocompatibility. For instance, new packaging materials may introduce residues that affect the device’s interaction with the body. Similarly, different sterilisation methods (whether autoclaving, gamma radiation, or ethylene oxide sterilisation) can degrade materials or release harmful by-products. These changes must be thoroughly assessed to ensure patient safety isn’t compromised.

Assessing the Risk of Medical Device Design Changes

Not all design changes carry the same risk. Manufacturers use risk evaluation to determine the extent of testing or validation required after a modification. Risks are generally categorised as follows:

• High Risk: Material changes, such as switching from one polymer to another, represent the highest risk. These alterations can significantly affect both local and systemic biological responses, particularly for implantable devices.

• Medium to High Risk: Modifications to manufacturing processes or the introduction of new additives (e.g., colorants or plasticisers) pose a medium-to-high risk. These changes can impact both local tissue interactions and long-term biological safety.

• Medium to Low Risk: Changing suppliers for existing materials carries lower risk, provided the new supplier meets the same quality standards and material specifications.

• Low Risk: A change in the source of a material, as long as the material itself remains unchanged, typically carries a low risk but still requires evaluation.
Higher-risk changes, such as material or geometric alterations, demand more extensive biocompatibility testing to ensure the safety of the final product. For implantable devices, these changes are particularly critical.

Weight of Evidence Approach

Rather than repeating a full suite of tests for every design change, many manufacturers use a Weight of Evidence approach. This method allows manufacturers to integrate new testing with existing biocompatibility data, potentially reducing the need for redundant tests. By comparing the modified device to its original version, manufacturers can justify the change with new data, provided it doesn’t introduce significant new risks. The type of evidence required depends on the nature of the change. For example, geometric changes may only affect local tissue responses, while material changes could impact both local and systemic effects. The Weight of Evidence approach streamlines the testing process while ensuring comprehensive safety assessments.

Summary

Biocompatibility is a cornerstone of medical device safety, and even small design changes can introduce new risks. As medical technologies evolve, manufacturers must rigorously assess the impact of design modifications on biocompatibility. This process involves identifying potential risks and mitigating them through thorough testing and validation. With careful evaluation and a strategic approach to risk management, manufacturers can
ensure that their devices remain safe for patients and effective in their intended applications. By adopting strategies like the Weight of Evidence approach and considering factors like material selection, surface treatments, and reprocessing procedures, manufacturers can maintain high safety standards even in the face of inevitable design changes. Ultimately, a well-managed biocompatibility review process helps ensure that medical devices continue to meet the highest safety standards, protecting patients and enhancing healthcare outcomes.

Explore how we can support your medical device journey to the market